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A COST-EFFECTIVENESS ANALYSIS OF
ELETRIPTAN 40MG AND 80MG VERSUS
SUMATRIPTAN 50MG AND 100MG IN THE
ACUTE TREATMENT OF MIGRAINE
Wells NEJ1, Drummond MF2
1Pﬁzer Global Research and Development, Sandwich, Kent,
United Kingdom; 2Innovus Research (UK) Ltd., and University
of York,York, United Kingdom
OBJECTIVES: To explore the application of cost-effec-
tiveness analysis in a comparison of eletriptan and suma-
triptan in the acute treatment of migraine employing a
composite measure of treatment outcome. METHODS:
The study is based on data from a randomised, double-
blind. placebo-controlled clinical trial comparison of oral
eletriptan (40mg and 80mg) and oral sumatriptan (50mg
and 100mg). The cost effectiveness analysis was under-
taken using the concept of “sustained pain-free” (SPF) 
to measure the outcome of treatment. SPF identiﬁes 
successful treatment as the combination of pain free
headache status at 2 hours after dosing, no recurrence
within 24 hours and no use of rescue medication. With
regard to costs, reﬂecting the health care system perspec-
tive of the analysis, drug costs for initial dosing, second
dosing for non-response and recurrence as well as the
costs of any rescue medication were taken into account.
RESULTS: The analysis found that eletriptan resulted in
lower costs per successfully treated attack (CPSTA) than
sumatriptan. The CPSTA values for the eletriptan 40mg
and 80mg groups were £17.55 and £31.76 compared
with ﬁgures for sumatriptan 50mg and 100mg of £63.98
and £80.50 respectively. All comparisons were statisti-
cally signiﬁcant (p < 0.024). CONCLUSIONS: The study
indicates that cost-effectiveness analysis can offer a
helpful framework for investigating the value-for-money
offered by the growing number of medicines for treating
migraine attacks. More speciﬁcally, its application to a
comparison of eletriptan and sumatriptan suggests that
the CPSTA for eletriptan 40mg is 27% of that found for
sumatriptan 50mg. Comparing eletriptan 80mg and
sumatriptan 100mg the corresponding value is 39%.
PNM8
ALZHEIMER’S DISEASE COST OF TREATMENT
STUDY (ADCOT) IN THE UNITED KINGDOM
Evans M1, Squires N2, Yuen C2
1Clatterbridge Hospital, Wirral, United Kingdom; 2Janssen-Cilag
Ltd, Buckinghamshire, United Kingdom
OBJECTIVES: To assess the resource utilisation of 
mild (MMSE 18 to 24), moderate (MMSE 11 to 17) and
severe (MMSE < 11), non-institutionalised patients with
Alzheimer’s disease in comparison with age, gender and
non-dementia disease-matched subjects. METHODS:
Resource utilisation data were collected on 146 patients
in the UK (120 with Alzheimer’s disease) by retrospective
review of clinical notes for a period of six months prior
to study entry, and by a single interview with the patient
and their carers. Direct medical resource use included
costs of hospitalisation, short-term institutionalisation,
medical consultations and medication. For direct non-
medical costs, utilisation of social services, equipment and
home modiﬁcations, personal expenses and transport
costs related to the illness were measured. For indirect
costs, time spent by the caregiver with the patient,
working days and productivity loss were evaluated. Costs
were assigned using 2001 UK pound sterling values.
RESULTS: Over the 6 month period, the total mean cost
per control subject was £1663 compared to £10,948 per
patient with mild, £14,176 per patient with moderate and
£16,626 per patient with severe Alzheimer’s disease. The
indirect cost of caregiving for Alzheimer’s patients was
the main component in all disease groups and represented
76%, 79%, and 70% of the total cost in the mild, 
moderate and severe disease groups, respectively. Within
direct costs, the contribution of short-term institutional-
isation accounted for 9% of total costs in the mild group,
increasing to 17% in the moderate and 34% in the severe
group (no control subjects required short-term institu-
tionalisation). Similarly, cost of hospitalisations increased
from 19% for patients with mild disease to 34% for
severe patients (4% for control group). CONCLUSIONS:
Resource utilisation by Alzheimer’s dementia patients is
signiﬁcantly greater than those without dementia and
increases with progression of disease.
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TIME SPENT AND COST ON INFORMAL CARE
GIVING FOR PERSONS WITH ALZHEIMER IN
SPAIN
Lopez Bastida J, Serrano Aguilar P,Yanes Lopez V,
Duque González B
Canarian Health Service, Santa Cruz de Tenerife, S/C de
Tenerife, Spain
OBJECTIVE: The objective of this study was to explore
the time spent and cost on caring by families of persons
with Alzheimer in Spain. METHODS: Questionnaires
were answered by 86 carers, caring for persons with
Alzheimer disease. Questions were focused on time spent
on caring: activities in daily living (ADL), instrumental
ADL (IADL), Social/recreational and Behaviour manage-
ment. The opportunity and replacement costs approaches
of informal care that occurred in 2001 in Spain were also
estimated. Disease stage was determined using the Clini-
cal Dementia Rating (CDR) scale. RESULTS: Informal
care, measured as hours spent caring, was about 293
hours per month for primary and secondary caregivers.
Approximately 32, 46, 9, and 16% of the total time of
informal support in ADL, IADL, Social/recreation and
Behaviour respectively. Informal care hours for mild,
moderate and severe Alzheimer patients were 196, 268
and 416 hours per month respectively. From the oppor-
tunity cost approach the annual cost for caregivers for
severe, moderate and mild patients were 16,274, 10,484
765Abstracts
and 7,668 euros respectively. For the replacement
approach the costs for severe, moderate and mild patients
were 25,333, 16,631, and 9,932 euros respectively. 
Informal support and costs, in terms of ADL, IADL,
Social/recreation and Behaviour increased with Alzheimer
severity. CONCLUSIONS: This study gives some new
perspectives on informal care giving for persons with
Alzheimer. Informal care for Alzheimer represent a sig-
niﬁcant hidden cost to Spanish society. This aspect of
caring must be addressed by the development of well-
targeted respite and relief support programmes. Because
the Spanish community is rapidly aging, this informal
care burden may increase signiﬁcantly in the future.
PNM10
COST EFFECTIVENESS OF MEMANTINE IN THE
TREATMENT OF MODERATELY SEVERE AND
SEVERE ALZHEIMER’S DISEASE IN SPAIN
Antonanzas F1, Badenas J2, François C3, Guilhaume C3
1University of La Rioja, Logroño, Logroño, Spain; 2H. Lundbeck
A/S, Barcelona, Spain; 3H. Lundbeck A/S, Paris, France
OBJECTIVES: Placebo-controlled clinical trials have
demonstrated the efﬁcacy of memantine versus placebo in
moderately severe and severe Alzheimer’s disease. A mod-
elling approach has been adopted to estimate costs and
outcomes of memantine treatment in clinical practice in
Spain. METHODS: A Markov model simulated moder-
ately severe and severe patients’ progression through
levels of combinations of severity, autonomy, and setting
over ﬁve years. Model inputs include clinical trial results
and measurement of patient and caregiver resource utili-
sation from a societal perspective using literature and
expert data. The main outcome measures were time spent
in autonomy (patient’s ability to accomplish activities
using the ADCS-ADL scale) and time to institutionalisa-
tion. This cost-effectiveness study compared the meman-
tine treatment strategy to that of no pharmacotherapy
and to donepezil for patients with moderately severe AD
followed by no pharmacotherapy when patients reach the
severe AD level. RESULTS: The time spent in autonomy
for patients treated with memantine is 14% longer in
duration than for patients treated with donepezil and
25% longer than for patients without pharmacotherapy.
The delay time to institutionalisation was 8% longer with
memantine compared with donepezil and 12% longer
with memantine compared with no treatment. Over a 5-
year period, patients treated with memantine showed a
decrease of €268 and €511 in total Health care costs,
compared with donepezil and no treatment, respectively.
Robustness of the results was validated by a comprehen-
sive sensitivity analysis. CONCLUSION: Memantine is
more effective in increasing time spent in autonomy and
in reducing Health care costs compared with donepezil or
no pharmacotherapy.
PNM11
IMPACT OF DEEP BRAIN STIMULATION (DBS)
OF THE SUBTHALAMIC NUCLEUS (STN) ON
HEALTH-RELATED QUALITY OF LIFE (HRQOL)
AND HEALTH CARE RESOURCE USE IN
ADVANCED PARKINSONIAN PATIENTS
Maurel F1, Ligier M2, Le Pen C2, Pollak P3
1CLP Santé, Paris, France; 2CLP-Santé, Paris, France; 3for The
French Spark Study Group, Grenoble, France
OBJECTIVES: To assess the impact of DBS of the STN
on HRQOL and on Health care resource use in French
advanced parkinsonian patients and to estimate the cost
of the procedure. METHODS: SPARK is an observational
prospective multicentre study using a before-after
methodology carried out between November 1998 and
March 2002 in a cohort of 88 patients with severe Parkin-
son’s disease (PD). Quality of life was assessed before
surgery and at 12-month follow-up using a speciﬁc instru-
ment, the PDQL 37 (Parkinson’s Disease Quality of Life)
that has a 3-month recall period. The resource use data
were monthly collected from individual questionnaires.
Two periods of observation were considered: the ﬁrst 6
months prior surgery and from the 6th to the 12th month
after surgery. The cost of the procedure (surgery, mater-
ial and checkups over 1 year) was assessed from data 
collected in the 4 centres. The economic analysis was 
performed from a Health Insurance perspective.
RESULTS: About 66% of patients were men. The mean
age of patients was 57.3 ± 7.7 years with a mean dura-
tion of PD of 13.9 ± 5.0 years. At 12-month follow-up
after surgery, the quality of life was signiﬁcantly improved
(+28%, p < 0.0001). All the PDQL subscores were con-
cerned by this improvement, especially the social dimen-
sion (+43.5%, p < 0.0001). The average 6-monthly cost
decreased from €10,087 ± 4,887 prior surgery to €1,673
± 2,111 after surgery (€-8,415 ± 4,438, p < 0.0001).
Taking into account costs related to adjustments of the
parameters of the stimulator, the difference was reduced
but remained signiﬁcant: €-7,275 ± 5,128 (p < 0.0001).
The most important savings came from a dramatically
decrease in medication use. CONCLUSIONS: Our ﬁnd-
ings showed a signiﬁcant impact of DBS on HRQOL and
on medical resource use in patients with PD.
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EARLY DECISION MAKING MODELLING IN
PARKINSON’S DISEASE—THE CASE OF NEURAL
TRANSPLANTATION IN PATIENTS WITH
ADVANCED PARKINSON’S DISEASE
Hjelmgren J1, Reimer J2, Persson U1, Ghatnekar O1,
Gabrowski M2, Lindvall O2, Hagell P2
1IHE, Lund, Sweden; 2Lund University Hospital, Lund, Sweden
OBJECTIVES: The purpose was to develop an early 
decision-making model for Parkinson disease (PD) and 
to assess the cost-effectiveness of neural transplanta-
tion (NT) compared to standard treatment in PD.
